Skyline Licenses TrovaGene Biomarker for AML | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Skyline Diagnostics has licensed rights to TrovaGene's NPM1 technology in Europe in a microarray test for use in helping guide acute myelogenous leukemia treatment, TrovaGene said today.

Skyline will use the TrovaGene nucleophosmin protein mutation, which is found in around 35 percent of AML patients and is associated with good disease prognosis, in its AMLprofiler in vitro diagnostic assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.